Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ARTES, Bio Farma in Vaccine Development Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

ARTES, Bio Farma in Vaccine Development Pact

Will use Metavax platform for vaccine candidates

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ARTES and Bio Farma have entered a collaboration for the development and manufacture of vaccine candidates. ARTES will apply its specialized cell line and process development and VLP based vaccine technology, Metavax, and Bio Farma will provide manufacturing of vaccines for the domestic Indonesian markets.
 
“We are extremely delighted about the mutually agreed collaboration. Bio Farma is a strong and reliable pharmaceutical partner and the only vaccine and antisera producer for humans in Indonesia. We are more than confident, that we along with Bio Farma will develop vaccines highly relevant for the Indonesian and neighboring markets. We expect that especially developments based on our Metavax technology will contribute to Bio Farma´s vaccine portfolio,” Dr. Michael Piontek, founder and managing director of ARTES Biotechnology.
 
ARTES´ Metavax platform is a VLP technology based on modifications to duck hepatitis B virus. The approach elicits a potent immune response and has the potential to offer broader protection than the currently available VLP approaches.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics